Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Server stories

Nov 3, 2026

Servier's $1.55 billion muscular dystrophy drug fails pivotal trial

Servier's sevasemten, acquired from Edgewise for $1.55 billion upfront in June 2026, failed its pivotal trial for muscular dystrophy just five months after the acquisition.

Nov 3, 2026·2 sources
00
Jun 1, 2026

Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business for Up to $2.65 Billion

French pharmaceutical company Servier will acquire Edgewise Therapeutics' experimental muscular dystrophy drug and related business for up to $2.65 billion. Edgewise will pivot to focus on cardiovascular drugs following the transaction.

Jun 1, 2026·2 sources
00

Top claims

  • ▪Servier purchased the experimental drug sevasemten from Edgewise Therapeutics in June 2026 for $1.55 billion in upfront cash, plus up to approximately $1 billion in potential milestones
  • ▪The experimental drug sevasemten, originally developed by Edgewise Therapeutics, had previously demonstrated promising results in a smaller randomized clinical study conducted before Servier's 2026 acquisition of the drug
  • ▪Servier's $1.55 billion acquisition of sevasemten failed its pivotal trial five months after the June 2026 deal with Edgewise Therapeutics was struck

Topics

Clinical trialsMergers and acquisitionsPharmaceutical IndustryRare diseasesMergers & acquisitions (M&A)Drug developmentGenetic diseasesPharma

Related entities

Grand CanyonFrance